{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:49:13Z","timestamp":1775695753678,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1D1A1A09916480"],"award-info":[{"award-number":["NRF-2016R1D1A1A09916480"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science & ICT","award":["M3A9B6069339"],"award-info":[{"award-number":["M3A9B6069339"]}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010955","name":"Kael-Gemvax","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010955","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck Serono"},{"name":"Teva-Handok"},{"name":"UCB"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bio & Medical Technology Development Program"},{"name":"Ministry of Science & ICT, Republic of Korea"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.neuint.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T02:57:28Z","timestamp":1543633048000},"page":"104347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"130","author":[{"given":"Su-Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Won","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2018.11.022_bib1","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","author":"Agius","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib2","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponseive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib5","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.neuint.2018.11.022_bib6","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.neuint.2018.11.022_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","article-title":"Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)","volume":"28","author":"Capobianco","year":"2007","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.neuint.2018.11.022_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00277-011-1369-y","article-title":"Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy","volume":"91","author":"Cornec","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.neuint.2018.11.022_bib14","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.11.022_bib15","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib16","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuint.2018.11.022_bib17","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","author":"Dunn","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib18","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.neuint.2018.11.022_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2016.11.016","article-title":"Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up","volume":"372","author":"Evangelopoulos","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib20","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neuint.2018.11.022_bib21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.neuint.2018.11.022_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","article-title":"Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders","volume":"324","author":"Ip","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib24","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib25","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1002\/art.38798","article-title":"Induction of interleukin-6 production by rituximab in human B cells","volume":"66","author":"Jones","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuint.2018.11.022_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000444161.12981.ba","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"82","author":"Kim","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.11.022_bib27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00415-014-7629-8","article-title":"Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder","volume":"262","author":"Kim","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib29","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jns.2012.05.005","article-title":"Lack of response to rituximab therapy in patients with neuromyelitis optica: true non-responders or insufficient treatment?","volume":"319","author":"Kim","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib32","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib33","article-title":"Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment","author":"Kim","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuint.2018.11.022_bib34","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1084\/jem.188.9.1679","article-title":"Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells","volume":"188","author":"Klein","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuint.2018.11.022_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders","author":"Lebrun","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.neuint.2018.11.022_bib36","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2018.11.022_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuint.2018.11.022_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuint.2018.11.022_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib40","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuint.2018.11.022_bib41","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","author":"Mealy","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuint.2018.11.022_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell-B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.neuint.2018.11.022_bib46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.neuint.2018.11.022_bib47","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial","volume":"45","author":"Ng","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuint.2018.11.022_bib48","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.11.022_bib50","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.neuint.2018.11.022_bib51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib52","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.11.022_bib53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib54","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/art.30599","article-title":"Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuint.2018.11.022_bib55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4049\/jimmunol.179.1.13","article-title":"Human IgM+CD27+ B cells: memory B cells or \u201cmemory\u201d B cells?","volume":"179","author":"Tangye","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuint.2018.11.022_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.022_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(79)90268-0","article-title":"Discontinuous density gradient separation of human mononuclear leucocytes using Percoll as gradient medium","volume":"30","author":"Ulmer","year":"1979","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.neuint.2018.11.022_bib58","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.neuint.2018.11.022_bib59","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.neuint.2018.11.022_bib60","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial Program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.neuint.2018.11.022_bib61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3899\/jrheum.111488","article-title":"Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion","volume":"40","author":"Vancsa","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.neuint.2018.11.022_bib62","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuint.2018.11.022_bib63","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuint.2018.11.022_bib64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.11.022_bib65","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrneurol.2011.154","article-title":"White matter disease: optimizing rituximab therapy for neuromyelitis optica","volume":"7","author":"Wingerchuk","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib66","first-page":"547","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"82","author":"Xu","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.11.022_bib67","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.11.022_bib68","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuint.2018.11.022_bib69","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618302973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618302973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:45:59Z","timestamp":1759311959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018618302973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":69,"alternative-id":["S0197018618302973"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2018.11.022","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104347"}}